Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.36 |
| ▸ | SLC5A7 | Q9GZV3 | 6/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2872264 | 0.76 | HRH3 (0.39) | HRH3CYP2D6 | |
| SCHEMBL2875024 | 0.75 | NR1H2 (0.36) | POLBKMT2A | |
| Lithium Ion SCHEMBL2875275 | 0.75 | HRH3 (0.41) | HRH3CYP2D6 | |
| SCHEMBL2875278 | 0.75 | HRH3 (0.42) | HRH3CYP2D6 | |
| SCHEMBL2874673 | 0.72 | SRD5A1 (0.41) | POLBKMT2A | |
| SCHEMBL5221628 | 0.69 | POLB (0.35) | POLBKMT2A | |
| SCHEMBL2878247 | 0.68 | HRH3 (0.65) | HRH3CYP2D6 | |
| Hydrochloric Acid SCHEMBL2872489 | 0.68 | HRH3 (0.46) | HRH3SLC5A7CYP1A2 | |
| SCHEMBL2875183 | 0.67 | HRH3 (0.53) | HRH3CYP2D6 | |
| SCHEMBL3166432 | 0.67 | PDE4B (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966199-B1 | AZAINDOLE-2-CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-10-20 | — | — | EP | disclosed |
| US-7622466-B2 | Azaindole-2-carboxamide derivatives | HOFFMAN-LA ROCHE INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090005379-A1 | Azaindole-2-Carboxamide Derivatives | HOFFMANN-LA ROCHE, INC. | 2009-01-01 | — | — | US | disclosed |
| EP-1966199-A1 | AZAINDOLE-2-CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007057329-A1 | AZAINDOLE-2-CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005379-A1 | Azaindole-2-Carboxamide Derivatives | HRH3, HRH4, H1-5 | HRH3 1/4885SLC5A7 565/4885CYP1A2 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.